Does the media favor TEVA or NUVL?

In the previous week, Teva Pharmaceutical Industries had 10 more articles in the media than Nuvalent. MarketBeat recorded 14 mentions for Teva Pharmaceutical Industries and 4 mentions for Nuvalent. Teva Pharmaceutical Industries' average media sentiment score of 1.24 beat Nuvalent's score of 0.72 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 11 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvalent 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RVMD or NUVL more profitable?

Nuvalent's return on equity of -40.11% beat Revolution Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Revolution Medicines N/A -83.22% -59.06% Nuvalent N/A -40.11% -35.43%

Does the media refer more to RVMD or NUVL?

In the previous week, Revolution Medicines had 5 more articles in the media than Nuvalent. MarketBeat recorded 9 mentions for Revolution Medicines and 4 mentions for Nuvalent. Nuvalent's average media sentiment score of 0.72 beat Revolution Medicines' score of 0.34 indicating that Nuvalent is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvalent 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ONC or NUVL?

In the previous week, BeOne Medicines had 11 more articles in the media than Nuvalent. MarketBeat recorded 15 mentions for BeOne Medicines and 4 mentions for Nuvalent. Nuvalent's average media sentiment score of 0.72 beat BeOne Medicines' score of 0.18 indicating that Nuvalent is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvalent 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NUVL or MRNA more profitable?

Nuvalent has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Nuvalent's return on equity. Company Net Margins Return on Equity Return on Assets Nuvalent N/A -40.11% -35.43% Moderna -143.55% -26.64% -19.32%

Does the media prefer NUVL or MRNA?

In the previous week, Moderna had 19 more articles in the media than Nuvalent. MarketBeat recorded 23 mentions for Moderna and 4 mentions for Nuvalent. Nuvalent's average media sentiment score of 0.72 beat Moderna's score of 0.52 indicating that Nuvalent is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 9 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NUVL or BNTX more profitable?

Nuvalent has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Nuvalent's return on equity. Company Net Margins Return on Equity Return on Assets Nuvalent N/A -40.11% -35.43% BioNTech -44.39% -5.30% -4.62%

Does the media prefer NUVL or BNTX?

In the previous week, Nuvalent and Nuvalent both had 4 articles in the media. BioNTech's average media sentiment score of 1.23 beat Nuvalent's score of 0.72 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Nuvalent (NUVL) Competitors

$123.52 -0.01 (-0.01%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$123.85 +0.33 (+0.27%)

As of 06/26/2026 06:58 PM Eastern

Compare

NUVL vs. TEVA, RVMD, ONC, MRNA, and BNTX

Should you buy Nuvalent stock or one of its competitors? MarketBeat compares Nuvalent with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuvalent include Teva Pharmaceutical Industries (TEVA), Revolution Medicines (RVMD), BeOne Medicines (ONC), Moderna (MRNA), and BioNTech (BNTX). These companies are all part of the "pharmaceutical products" industry.

How does Nuvalent compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

In the previous week, Teva Pharmaceutical Industries had 10 more articles in the media than Nuvalent. MarketBeat recorded 14 mentions for Teva Pharmaceutical Industries and 4 mentions for Nuvalent. Teva Pharmaceutical Industries' average media sentiment score of 1.24 beat Nuvalent's score of 0.72 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	11 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvalent	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Teva Pharmaceutical Industries has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.21	$1.41B	$1.33	24.99
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Teva Pharmaceutical Industries has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, Nuvalent has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Nuvalent's net margin of 0.00%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
Nuvalent	N/A	-40.11%	-35.43%

Teva Pharmaceutical Industries presently has a consensus price target of $41.78, indicating a potential upside of 25.68%. Nuvalent has a consensus price target of $127.73, indicating a potential upside of 3.41%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, equities analysts plainly believe Teva Pharmaceutical Industries is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Comparatively, 5.0% of Nuvalent shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Teva Pharmaceutical Industries beats Nuvalent on 12 of the 15 factors compared between the two stocks.

How does Nuvalent compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Nuvalent's return on equity of -40.11% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Nuvalent	N/A	-40.11%	-35.43%

Revolution Medicines has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Nuvalent has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Comparatively, 5.0% of Nuvalent shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Revolution Medicines had 5 more articles in the media than Nuvalent. MarketBeat recorded 9 mentions for Revolution Medicines and 4 mentions for Nuvalent. Nuvalent's average media sentiment score of 0.72 beat Revolution Medicines' score of 0.34 indicating that Nuvalent is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvalent	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvalent has lower revenue, but higher earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,342.85	-$1.13B	-$7.07	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Revolution Medicines currently has a consensus target price of $123.72, indicating a potential downside of 32.05%. Nuvalent has a consensus target price of $127.73, indicating a potential upside of 3.41%. Given Nuvalent's higher probable upside, analysts clearly believe Nuvalent is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15

Summary

Nuvalent beats Revolution Medicines on 8 of the 15 factors compared between the two stocks.

How does Nuvalent compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

BeOne Medicines has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Nuvalent has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

BeOne Medicines has a net margin of 8.94% compared to Nuvalent's net margin of 0.00%. BeOne Medicines' return on equity of 12.06% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Nuvalent	N/A	-40.11%	-35.43%

BeOne Medicines has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	5.75	$286.93M	$4.47	62.62
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

In the previous week, BeOne Medicines had 11 more articles in the media than Nuvalent. MarketBeat recorded 15 mentions for BeOne Medicines and 4 mentions for Nuvalent. Nuvalent's average media sentiment score of 0.72 beat BeOne Medicines' score of 0.18 indicating that Nuvalent is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvalent	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BeOne Medicines currently has a consensus price target of $390.00, indicating a potential upside of 39.34%. Nuvalent has a consensus price target of $127.73, indicating a potential upside of 3.41%. Given BeOne Medicines' stronger consensus rating and higher possible upside, research analysts plainly believe BeOne Medicines is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by insiders. Comparatively, 5.0% of Nuvalent shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

BeOne Medicines beats Nuvalent on 13 of the 16 factors compared between the two stocks.

How does Nuvalent compare to Moderna?

Nuvalent (NASDAQ:NUVL) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

Nuvalent has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Moderna	-143.55%	-26.64%	-19.32%

Nuvalent presently has a consensus price target of $127.73, indicating a potential upside of 3.41%. Moderna has a consensus price target of $37.13, indicating a potential downside of 44.80%. Given Nuvalent's stronger consensus rating and higher possible upside, equities analysts clearly believe Nuvalent is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

In the previous week, Moderna had 19 more articles in the media than Nuvalent. MarketBeat recorded 23 mentions for Moderna and 4 mentions for Nuvalent. Nuvalent's average media sentiment score of 0.72 beat Moderna's score of 0.52 indicating that Nuvalent is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	9 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvalent has higher earnings, but lower revenue than Moderna. Nuvalent is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Moderna	$1.94B	13.73	-$2.82B	-$8.15	N/A

97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 5.0% of Nuvalent shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Nuvalent has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, Moderna has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

Summary

Nuvalent beats Moderna on 9 of the 15 factors compared between the two stocks.

How does Nuvalent compare to BioNTech?

Nuvalent (NASDAQ:NUVL) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

Nuvalent has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
BioNTech	-44.39%	-5.30%	-4.62%

Nuvalent has higher earnings, but lower revenue than BioNTech. Nuvalent is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
BioNTech	$3.25B	7.11	-$1.29B	-$5.88	N/A

Nuvalent presently has a consensus target price of $127.73, suggesting a potential upside of 3.41%. BioNTech has a consensus target price of $129.56, suggesting a potential upside of 42.03%. Given BioNTech's stronger consensus rating and higher possible upside, analysts plainly believe BioNTech is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

In the previous week, Nuvalent and Nuvalent both had 4 articles in the media. BioNTech's average media sentiment score of 1.23 beat Nuvalent's score of 0.72 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvalent has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market.

97.3% of Nuvalent shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 5.0% of Nuvalent shares are held by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

BioNTech beats Nuvalent on 12 of the 15 factors compared between the two stocks.

Get Nuvalent News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NUVL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NUVL vs. The Competition

Export

Metric	Nuvalent	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.76B	$3.63B	$7.04B	$12.19B
Dividend Yield	N/A	2.21%	2.66%	6.23%
P/E Ratio	-20.38	21.56	26.13	24.17
Price / Sales	N/A	334.26	556.13	101.82
Price / Cash	N/A	141.14	47.95	55.62
Price / Book	7.74	8.33	10.78	6.36
Net Income	-$425.38M	$23.91M	$3.58B	$337.99M
7 Day Performance	0.07%	3.42%	2.22%	0.10%
1 Month Performance	13.04%	0.39%	-0.09%	-1.28%
1 Year Performance	55.02%	65.22%	34.39%	27.68%

Nuvalent Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NUVL Nuvalent	2.4489 of 5 stars	$123.52 0.0%	$127.73 +3.4%	+55.0%	$9.76B	N/A	N/A	40	Analyst Downgrade Short Interest Decrease
TEVA Teva Pharmaceutical Industries	4.8543 of 5 stars	$32.25 +2.4%	$41.78 +29.6%	+98.4%	$36.20B	$17.35B	24.24	33,950	Options Volume
RVMD Revolution Medicines	1.6662 of 5 stars	$165.81 +1.7%	$123.72 -25.4%	+393.3%	$34.65B	$11.58M	N/A	250	Insider Trade Options Volume
ONC BeOne Medicines	4.7778 of 5 stars	$271.80 +0.6%	$390.00 +43.5%	+16.0%	$29.64B	$5.34B	60.81	12,000	News Coverage Analyst Upgrade Insider Trade
MRNA Moderna	1.1186 of 5 stars	$59.35 -7.2%	$36.60 -38.3%	+147.7%	$25.38B	$1.94B	N/A	4,700	Trending News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NUVL) was last updated on 6/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvalent (NUVL) Competitors

NUVL vs. TEVA, RVMD, ONC, MRNA, and BNTX

How does Nuvalent compare to Teva Pharmaceutical Industries?

Summary

How does Nuvalent compare to Revolution Medicines?

Summary

How does Nuvalent compare to BeOne Medicines?

Summary

How does Nuvalent compare to Moderna?

Summary

How does Nuvalent compare to BioNTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVL vs. The Competition

Nuvalent Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvalent (NUVL) Competitors

NUVL vs. TEVA, RVMD, ONC, MRNA, and BNTX

How does Nuvalent compare to Teva Pharmaceutical Industries?

Does the media favor TEVA or NUVL?

Which has preferable earnings & valuation, TEVA or NUVL?

Which has more risk and volatility, TEVA or NUVL?

Is TEVA or NUVL more profitable?

Do analysts rate TEVA or NUVL?

Do insiders & institutionals have more ownership in TEVA or NUVL?

Summary

How does Nuvalent compare to Revolution Medicines?

Is RVMD or NUVL more profitable?

Which has more volatility and risk, RVMD or NUVL?

Do institutionals and insiders have more ownership in RVMD or NUVL?

Does the media refer more to RVMD or NUVL?

Which has stronger valuation & earnings, RVMD or NUVL?

Do analysts recommend RVMD or NUVL?

Summary

How does Nuvalent compare to BeOne Medicines?

Which has more risk & volatility, ONC or NUVL?

Is ONC or NUVL more profitable?

Which has better earnings and valuation, ONC or NUVL?

Does the media refer more to ONC or NUVL?

Do analysts recommend ONC or NUVL?

Do institutionals & insiders have more ownership in ONC or NUVL?

Summary

How does Nuvalent compare to Moderna?

Is NUVL or MRNA more profitable?

Do analysts prefer NUVL or MRNA?

Does the media prefer NUVL or MRNA?

Which has preferable valuation & earnings, NUVL or MRNA?

Do institutionals and insiders believe in NUVL or MRNA?

Which has more risk & volatility, NUVL or MRNA?

Summary

How does Nuvalent compare to BioNTech?

Is NUVL or BNTX more profitable?

Which has higher earnings and valuation, NUVL or BNTX?

Do analysts recommend NUVL or BNTX?

Does the media prefer NUVL or BNTX?

Which has more volatility and risk, NUVL or BNTX?

Do insiders and institutionals believe in NUVL or BNTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVL vs. The Competition

Nuvalent Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools